Browsing Tag
Greater China
9 posts
Marriott opens The Dali EDITION as China luxury strategy moves beyond gateway cities
Marriott opens The Dali EDITION in Yunnan, deepening its China luxury push. Discover what the 151-room launch means for growth, rivals and MAR investors now
ACROBiosystems just removed a quiet bottleneck in drug discovery. Will biopharma buyers notice?
Biopharma wants faster R&D, but compliance still slows labs. ACROBiosystems is turning HEK293 licensing into a workflow advantage.
Adidas Q1 2026 beats Street with €705m operating profit and 14% currency-neutral growth as ADS Xetra rallies 9% on FIFA World Cup tailwind
Adidas beat Q1 2026 consensus with €705m operating profit, but held 2026 guidance flat. The unbooked €300m tariff item is the real story for ADS investors.
Procter & Gamble (NYSE: PG) beats Q3 estimates on beauty momentum but Andre Schulten flags billion-dollar oil headwind for fiscal 2027
Procter & Gamble beat Q3 estimates, but a $1 billion fiscal 2027 oil warning is the harder question for investors banking on a clean earnings reset.
Nike (NYSE: NKE) at 11-year lows: Is the Swoosh a value trap or a 2027 recovery bet?
Nike (NKE) is trading at USD 42.62, near 11-year lows. Tariffs, China and a delayed turnaround have rattled investors. Here is what the next catalyst means for NKE shareholders.
Nike (NYSE: NKE) posts flat Q3 revenue as China drag deepens and North America comeback accelerates
Nike Q3 FY26: $11.3B revenue, NKE stock near 52-week low after China -20% Q4 guide. Read the full strategic breakdown of earnings, tariffs, and recovery timeline.
Apple just had its best quarter ever—what pushed iPhone sales over the top?
Apple posted record Q1 FY2026 earnings with $143.8B in revenue and $2.84 EPS. Find out what drove the surge and what it signals for 2026 growth.
Can AI fix health insurance claims? Bupa bets on Cognizant’s BPaaS engine
Bupa Hong Kong teams up with Cognizant for a five-year AI-driven BPaaS deal to transform claims processing and compliance. Find out what’s changing and why.
Sanofi strengthens cardiovascular portfolio with Aficamten rights in Greater China
Cytokinetics, Incorporated (NASDAQ: CYTK) saw its shares climb by 4.8% after announcing a landmark agreement with Sanofi (NASDAQ:…